Study of Safety and Effects of Single Increasing Doses of NNC0113-5840 in Adults with Overweight or Obesity Aged 18 to 55

What this Trial Is About

Researchers are investigating the safety and tolerability of NNC0113-5840, a new medicine being studied for people who are overweight or have obesity. This Phase 1 clinical trial aims to understand how this medicine works in the body and assess any side effects. The study involves participants who have a body mass index BMI between 25.0 and 34.9 kgm2 and are between 18 and 55 years old. Participants will be randomly assigned to receive one of six different single dose levels of NNC0113-5840 or a placebo, both given by subcutaneous injection in the abdominal area using a needle and syringe. This sequential study compares the effects of various doses of the new medicine against a placebo. Each participant will receive only one dose. During the study, participants will be monitored from the day of dosing up to 43 days afterward. Researchers will track any treatment-emergent adverse events to evaluate safety. They will also measure how the medicine is processed in the body by assessing plasma concentration levels. Participants will have medical exams, vital signs checks, electrocardiograms, and laboratory tests to monitor their health throughout the study period.

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity